Delia Deschaine, Member of the Firm, and Kala Shankle, Associate, co-present "The Impact of Roe v. Wade's Reversal on Pharmacies and Pharmacists" at an American Society for Pharmacy Law roundtable discussion.
In June 2022, the Supreme Court of the United States issued a landmark decision in Dobbs v. Jackson Women's Health Organization when it held that the U.S. Constitution does not confer a right to abortion and overruled precedent set in both Roe v. Wade and Planned Parenthood v. Casey. With almost half of abortions in the U.S. occurring via medication, the Dobbs decision has prompted several questions regarding the role and scope of pharmacies and pharmacists in dispensing reproductive medications for either on or off label use, while complying with applicable state law, in a post-Roe world.
This panel analyzes the Dobbs decision through the lens of questions that have arisen regarding federal and state laws impacting the distribution and dispensing of pregnancy terminating medications (e.g., Mifepristone and Misoprostol), as well as other medication used for reproductive health (e.g., Plan B). They also examine federal and specific state laws that have limited or expanded the pharmacist’s role in dispensing (or refusing to dispense) abortifacients and other reproductive health medications.
For more information and to register, please visit ASPL.org.
